These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Vigorita VJ; Silver JS; Eisemon EO Skeletal Radiol; 2012 Jul; 41(7):861-5. PubMed ID: 22526880 [TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Jobke B; Milovanovic P; Amling M; Busse B Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427 [TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Amerling R; Harbord NB; Pullman J; Feinfeld DA Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316 [TBL] [Abstract][Full Text] [Related]
6. [Bisphosphonate therapy in osteoporosis. Inhibition of trabecular perforation by aminobisphosphonate]. Wüster C; Heilmann P Fortschr Med; 1997 Oct; 115(29):37-42. PubMed ID: 9445833 [TBL] [Abstract][Full Text] [Related]
7. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. La Rocca Vieira R; Rosenberg ZS; Allison MB; Im SA; Babb J; Peck V AJR Am J Roentgenol; 2012 May; 198(5):1144-51. PubMed ID: 22528906 [TBL] [Abstract][Full Text] [Related]
8. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170 [TBL] [Abstract][Full Text] [Related]
9. Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts. Shu G; Yamamoto K; Nagashima M Mod Rheumatol; 2006; 16(6):343-9. PubMed ID: 17164994 [TBL] [Abstract][Full Text] [Related]
10. [Osteonecrosis of the jaws by long term therapy with bisphosphonates]. Piesold JU; Al-Nawas B; Grötz KA Mund Kiefer Gesichtschir; 2006 Sep; 10(5):287-300. PubMed ID: 16960697 [TBL] [Abstract][Full Text] [Related]
11. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Adler RA; El-Hajj Fuleihan G; Bauer DC; Camacho PM; Clarke BL; Clines GA; Compston JE; Drake MT; Edwards BJ; Favus MJ; Greenspan SL; McKinney R; Pignolo RJ; Sellmeyer DE J Bone Miner Res; 2016 Jan; 31(1):16-35. PubMed ID: 26350171 [TBL] [Abstract][Full Text] [Related]
12. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. Landman JO; Hamdy NA; Pauwels EK; Papapoulos SE J Clin Endocrinol Metab; 1995 Dec; 80(12):3465-8. PubMed ID: 8530584 [TBL] [Abstract][Full Text] [Related]
13. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis. Koek WNH; van der Eerden BCJ; Alves RDAM; van Driel M; Schreuders-Koedam M; Zillikens MC; van Leeuwen JPTM Bone; 2017 Feb; 95():108-114. PubMed ID: 27845263 [TBL] [Abstract][Full Text] [Related]
14. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. Landman JO; Papapoulos SE Osteoporos Int; 1995 Mar; 5(2):93-6. PubMed ID: 7599454 [TBL] [Abstract][Full Text] [Related]
15. [Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?]. Mehl B; Delling G; Schlindwein I; Heilmann P; Voia C; Ziegler R; Nawroth P; Kasperk C Med Klin (Munich); 2002 Oct; 97(10):588-94. PubMed ID: 12386791 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of long-term treatment with bisphosphonate for osteoporosis in Japanese]. Kushida K Nihon Rinsho; 2004 Feb; 62 Suppl 2():455-60. PubMed ID: 15035170 [No Abstract] [Full Text] [Related]
17. High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman. Muschitz C; Roschger P; Patsch J; Pollhammer I; Koller B; Klaushofer K; Resch H Wien Med Wochenschr; 2007; 157(15-16):388-91. PubMed ID: 17922087 [TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. Hernández MV; Peris P; Monegal A; Reyes R; Muxi A; Gifre L; Guañabens N Am J Med Sci; 2010 Mar; 339(3):225-9. PubMed ID: 20220332 [TBL] [Abstract][Full Text] [Related]
19. THE INFLUENCE OF AGE AND OF DURATION OF TREATMENT ON THE PRODUCTION AND REPAIR OF BONE LESIONS IN EXPERIMENTAL HYPERPARATHYROIDISM. Jaffe HL; Bodansky A; Blair JE J Exp Med; 1932 Jan; 55(1):139-54. PubMed ID: 19869973 [TBL] [Abstract][Full Text] [Related]
20. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Glendenning P; Kent GN; Adler BD; Matz L; Watson I; O'Driscoll GJ; Hurley DM Clin Endocrinol (Oxf); 1999 Mar; 50(3):347-55. PubMed ID: 10435061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]